Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 2
1998 2
1999 2
2000 1
2001 3
2002 1
2003 2
2004 1
2005 1
2006 1
2007 2
2008 3
2009 5
2010 1
2011 3
2012 9
2013 8
2014 9
2015 9
2016 3
2017 4
2018 4
2019 16
2020 29
2021 23
2022 20
2023 22
2024 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Immunotherapy for non-small cell lung cancer.
Kagamu H. Kagamu H. Respir Investig. 2024 Mar;62(2):307-312. doi: 10.1016/j.resinv.2024.01.011. Epub 2024 Feb 3. Respir Investig. 2024. PMID: 38310751 Review.
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K. Saito R, et al. Among authors: kagamu h. Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36966696 Free article. Clinical Trial.
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T. Watanabe S, et al. Among authors: kagamu h. Eur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2. Eur J Cancer. 2024. PMID: 38061214 Clinical Trial.
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: kagamu h. Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5. Sci Rep. 2023. PMID: 38012343 Free PMC article.
Paraneoplastic striatal encephalitis.
Oguma T, Kobayashi H, Katada S, Onodera O, Tanaka K, Tsuji S, Uno T, Ishida T, Kagamu H, Gejyo F, Motomura M. Oguma T, et al. Among authors: kagamu h. Neurology. 2001 Dec 26;57(12):2326. doi: 10.1212/wnl.57.12.2326. Neurology. 2001. PMID: 11756629 No abstract available.
193 results